Preferred Label : evolocumab;
MeSH note : targets PCSK9;
CISMeF synonym : AMG-145;
MeSH hyponym : AMG 145;
Is substance : O;
UNII : LKC0U3A8NJ;
Origin ID : C577155;
UMLS CUI : C3529352;
ATC code(s)
CISMeF manual mappings
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also (suggested by CISMeF)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3506440/fr/repatha-evolocumab-hypercholesterolemie
2024
false
false
false
France
evaluation of the transparency committee
repatha
Hypercholesterolemia
hypercholesterolemia
evolocumab
Evolocumab
evolocumab
hypercholesterolemia, nos
---
https://www.has-sante.fr/jcms/p_3338762/fr/repatha-evolocumab-hypercholesterolemie-familiale-heterozygote-hfhe
2022
false
false
false
France
Familial hypercholesterolemia - heterozygous (disorder)
insurance, health, reimbursement
treatment outcome
evolocumab
child
adolescent
drug therapy, combination
Homozygous Familial Hypercholesterolemia
injections, subcutaneous
evaluation of the transparency committee
hyperlipoproteinemia type ii
evolocumab
high serum cholesterol, familial
---
https://www.has-sante.fr/jcms/p_3313603/fr/repatha-evolocumab
2022
false
false
false
France
insurance, health, reimbursement
antibodies, monoclonal
antibodies, monoclonal, humanized
hydroxymethylglutaryl-coa reductase inhibitors
Ezetimibe
adult
Atherosclerotic cardiovascular disease
Heterozygous familial hypercholesterolemia
evaluation of the transparency committee
evolocumab
---
https://www.has-sante.fr/portail/jcms/c_2869374/fr/repatha
2018
false
false
false
false
France
French
evaluation of the transparency committee
repatha
evolocumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2879791/fr/repatha
2018
false
false
false
France
hypercholesterolemia
dyslipidemias
injections, subcutaneous
evolocumab
treatment outcome
evaluation of the transparency committee
repatha
evolocumab
antibodies, monoclonal
evolocumab
antibodies, monoclonal
---
https://minerva-ebp.be/FR/Article/2143
2017
false
false
false
false
Belgium
French
critical appraisal or critical reading
evolocumab
evolocumab
PCSK9 protein, human
cardiovascular diseases
drug therapy, combination
treatment outcome
hydroxymethylglutaryl-coa reductase inhibitors
hypercholesterolemia
anticholesteremic agents
hypercholesterolemia
cholesterol, LDL
cardiovascular diseases
antibodies, monoclonal
---
http://www.has-sante.fr/portail/jcms/c_2586918/fr/repatha
http://www.has-sante.fr/portail/jcms/c_2586918/en/repatha-evolocumab-anti-pcsk9
https://www.has-sante.fr/portail/jcms/c_2586918/fr/repatha-evolocumab-anti-pcsk9
2016
false
false
false
France
French
evolocumab
evolocumab
evolocumab
evaluation of the transparency committee
adult
adolescent
drug therapy, combination
Familial hypercholesterolemia - homozygous (disorder)
hyperlipoproteinemia type ii
hypercholesterolemia
insurance, health, reimbursement
treatment outcome
Primary hypercholesterolemia (disorder)
hypolipidemic agents
dyslipidemias
injections, subcutaneous
guidelines for drug use
PCSK9 protein, human
repatha
antibodies, monoclonal
antibodies, monoclonal
serine endopeptidases
proprotein convertases
evolocumab
antibodies, monoclonal
---
Summary Basis of Decision (SBD) for Repatha
Evolocumab, 140 mg/mL, solution, subcutaneous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00242
2016
false
false
false
false
Canada
French
English
evolocumab
evolocumab
adult
adolescent
drug therapy, combination
Familial hypercholesterolemia - homozygous (disorder)
hyperlipoproteinemia type ii
hypercholesterolemia
treatment outcome
Primary hypercholesterolemia (disorder)
hypolipidemic agents
dyslipidemias
injections, subcutaneous
PCSK9 protein, human
drug information
drug approval
canada
antibodies, monoclonal
serine endopeptidases
proprotein convertases
Proprotein Convertase 9
---
https://www.ema.europa.eu/medicines/human/EPAR/Repatha
2015
false
false
false
United Kingdom
French
English
evolocumab
evolocumab
evolocumab
adult
adolescent
drug therapy, combination
Familial hypercholesterolemia - homozygous (disorder)
hyperlipoproteinemia type ii
hypercholesterolemia
treatment outcome
Primary hypercholesterolemia (disorder)
hypolipidemic agents
dyslipidemias
injections, subcutaneous
PCSK9 protein, human
repatha
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
pregnancy
breast feeding
drug interactions
mixed dyslipidemia
Familial hypercholesterolemia - heterozygous (disorder)
antibodies, monoclonal
antibodies, monoclonal
serine endopeptidases
proprotein convertases
evolocumab
antibodies, monoclonal
Proprotein Convertase 9
---